Nutra Pharma Corp.
NPHC
$0.00
$0.000.00%
OTC PK
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 48.20K | 54.10K | 98.70K | 122.10K | 110.40K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 48.20K | 54.10K | 98.70K | 122.10K | 110.40K |
| Cost of Revenue | 29.20K | 66.00K | 34.10K | 46.50K | 51.30K |
| Gross Profit | 19.00K | -11.90K | 64.60K | 75.60K | 59.10K |
| SG&A Expenses | 398.20K | 454.00K | 420.70K | 366.20K | 409.00K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 427.50K | 520.00K | 454.80K | 412.70K | 460.20K |
| Operating Income | -379.20K | -465.90K | -356.10K | -290.50K | -349.80K |
| Income Before Tax | -459.70K | -488.50K | -523.50K | 369.60K | -1.40M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -459.70K | -488.50K | -523.50K | 369.60K | -1.40M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -459.70K | -488.50K | -523.50K | 369.60K | -1.40M |
| EBIT | -379.20K | -465.90K | -356.10K | -290.50K | -349.80K |
| EBITDA | -376.70K | -463.30K | -353.30K | -287.40K | -347.70K |
| EPS Basic | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Normalized Basic EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Normalized Diluted EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average Basic Shares Outstanding | 8.01B | 7.88B | 7.82B | 7.74B | 7.68B |
| Average Diluted Shares Outstanding | 8.01B | 7.88B | 7.82B | 37.73B | 7.68B |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |